Authored By: Sarah
11 Jul 2024

 Antibody Drug Conjugates Market to grow by USD 9.95 billion between 2024-2028

According to a research report “ Antibody Drug Conjugates Market” by Application (Breast cancer, Blood cancer, Others) Technology (Cleavable linker, Non-cleavable linker, Linkerless) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 9.95 billion at a CAGR of  15.06% during the forecast period. The Antibody Drug Conjugates (ADCs) market in North America is experiencing robust growth, driven by the region's substantial pharmaceutical industry, advanced healthcare infrastructure, and favorable reimbursement policies. With a significant number of players and the highest prevalence of cancer, the US leads the North American market, which is projected to expand significantly over the coming years due to the high demand for targeted cancer treatments..

Browse market data tables, figures, and in-depth TOC on “Antibody Drug Conjugates Market” by Application (Breast cancer, Blood cancer, Others) Technology (Cleavable linker, Non-cleavable linker, Linkerless) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By Application, the Breast cancer segment is projected to dominate the market size in 2024.

In the Antibody Drug Conjugates (ADC) market, the cleavable linker segment plays a pivotal role. ADCs represent a groundbreaking class of therapeutics, merging the potency of small-molecule drugs with the precision of monoclonal antibodies. The cleavable linker, which bridges the cytotoxic payload and the antibody, is essential for targeted drug delivery. It must efficiently and selectively cleave within the cancer cell for therapeutic efficacy, while remaining stable during circulation to prevent untimely drug release. Various mechanisms, including enzymatic cleavage and disulfide bond elimination, can trigger this cleavage process.

By Technology, Cleavable linker  segment is expected to hold the largest market size for the year 2024.

In the dynamic global Antibody Drug Conjugates (ADC) market, the breast cancer segment holds substantial significance due to its rapid expansion. ADCs represent a revolutionary class of targeted cancer therapies, merging the potent chemotherapeutic properties of medicines with the precision of monoclonal antibodies. Given the prevalence and high morbidity rate of breast cancer among women, accounting for a considerable share of cancer-related fatalities, the development of efficient and focused breast cancer treatment options is crucial. ADCs offer a promising solution by specifically targeting cancer cells and delivering cytotoxic agents directly to tumor sites.

North America is forecasted to hold the largest market size by region in 2024.

The Antibody Drug Conjugates (ADCs) market in North America is experiencing robust growth, driven by the region's substantial pharmaceutical industry, advanced healthcare infrastructure, and favorable reimbursement policies. With a significant number of players and the highest prevalence of cancer, the US leads the North American market, projected to expand further due to the increasing demand for targeted cancer therapies.

The Antibody Drug Conjugates Market t growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Adcendo ApS
  • Araris Biotech AG
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • ImmunoGen Inc.
  • Merck KGaA
  • Mersana Therapeutics Inc.
  • Mythic Therapeutics
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • PPF Group
  • Regeneron Pharmaceuticals Inc.
  • Seagen Inc.
  • Syngene International Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • ADC Therapeutics SA
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Antibody Drug Conjugates (ADCs) market represents a significant segment in the biopharmaceutical industry, driven by advancements in immunotherapy and chemotherapy. ADCs are formed by the covalent attachment of cytotoxic drugs to monoclonal antibodies or multi-specific antibodies, enabling targeted delivery to tumour cells. The linker plays a crucial role in the conjugation process, ensuring the stability and release of the payload in the tumour microenvironment. The ADCs market encompasses various types of conjugation technologies, including polymer-drug conjugation, protein-drug conjugation, and carbohydrate-drug conjugation. These technologies leverage the unique properties of polymers, lipids, proteins, polypeptides, and drugs to optimize the pharmacokinetics and enhance the therapeutic efficacy. Angiogenesis inhibitors are often used in combination with ADCs to modulate the immune system and improve treatment outcomes. The global ADCs market is expected to grow substantially due to the increasing demand for targeted therapies and the ongoing research and development efforts in this field. The market's growth is further fueled by the potential of ADCs to address the limitations of traditional chemotherapy and immunotherapy, such as off-target effects and resistance.

Market Research Overview

The Antibody Drug Conjugates (ADCs) market represents a significant segment in the biopharmaceutical industry, driven by the advancements in bioconjugation technology and the development of innovative therapeutics. ADCs are composed of a monoclonal antibody, a chemical linker, and a cytotoxic payload, designed to target tumor cells with high specificity. These conjugates leverage the antibody's ability to recognize surface antigens on tumor cells, enabling efficient delivery of the cytotoxic payload to the tumor site. ADCs employ various linker and payload strategies, including cleavable and non-cleavable linkers, and polymers, lipids, proteins, or polypeptides as carriers. Some notable ADCs include Valine Citrulline (VC)-DM4, MMAE, loncastuximab tesirine-lpyl (Zynlonta), disitamab vedotin (Aidixi), cetuximab sarotalocan (Akalux), tisotumab vedotin (Tivdak), mirvetuximab soravtansine (Elahere), belantamab mafodotin-blmf (Blenrep), trastuzumab deruxtecan (Enhertu), sacituzumab govitecan (Trodelvy), enfortumab vedotin (Padcev), polatuzumab vedotin-piiq (Polivy), gemtuzumab ozogamicin (Mylotarg), inotuzumab ozogamicin (Besponsa), brentuximab vedotin (Adcetris), ado-trastuzumab emtansine (Kadcyla), and various other bioconjugated therapeutics. The ADC market is continually evolving, with ongoing research and development in antibody-drug conjugation, pharmacokinetics, and protein-drug conjugation, aiming to improve the efficacy, safety, and specificity of these therapeutic agents.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio
Document